387 related articles for article (PubMed ID: 21879778)
1. Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review.
Jones SC; Sorbello A; Boucher RM
Drug Saf; 2011 Oct; 34(10):839-47. PubMed ID: 21879778
[TBL] [Abstract][Full Text] [Related]
2. [Fluoroquinolone associated myasthenia gravis exacerbation: clinical analysis of 9 cases].
Wang SH; Xie YC; Jiang B; Zhang JY; Qu Y; Zhao Y; Li Y; Qiao SS; Xu CL
Zhonghua Yi Xue Za Zhi; 2013 May; 93(17):1283-6. PubMed ID: 24029473
[TBL] [Abstract][Full Text] [Related]
3. [Exacerbation of myasthenia gravis by pefloxacin].
Vial T; Chauplannaz G; Brunel P; Leriche B; Evreux JC
Rev Neurol (Paris); 1995 Apr; 151(4):286-7. PubMed ID: 7481384
[TBL] [Abstract][Full Text] [Related]
4. Prulifloxacin as a trigger of myasthenia gravis.
Rossi M; Lusini G; Biasella A; Mazzocchio R
J Neurol Sci; 2009 May; 280(1-2):109-10. PubMed ID: 19232642
[TBL] [Abstract][Full Text] [Related]
5. Emergency Department Management of a Myasthenia Gravis Patient with Community-Acquired Pneumonia: Does Initial Antibiotic Choice Lead to Cure or Crisis?
Van Berkel MA; Twilla JD; England BS
J Emerg Med; 2016 Feb; 50(2):281-5. PubMed ID: 26472607
[TBL] [Abstract][Full Text] [Related]
6. Pharmacosafety of fluoroquinolone and macrolide antibiotics in the clinical care of patients with myasthenia gravis.
Pham Nguyen TP; Leonard CE; Bird SJ; Willis AW; Hamedani AG
Muscle Nerve; 2021 Aug; 64(2):156-162. PubMed ID: 33719062
[TBL] [Abstract][Full Text] [Related]
7. Glucose homeostasis abnormalities associated with use of gatifloxacin.
Frothingham R
Clin Infect Dis; 2005 Nov; 41(9):1269-76. PubMed ID: 16206101
[TBL] [Abstract][Full Text] [Related]
8. Suspected Fluoroquinolone-Induced Exacerbation of Myasthenia Gravis in Dogs.
Guzman KMH; Harkin K
J Am Anim Hosp Assoc; 2023 Sep; 59(5):249-254. PubMed ID: 37708471
[TBL] [Abstract][Full Text] [Related]
9. Fluoroquinolone-associated tendon-rupture: a summary of reports in the Food and Drug Administration's adverse event reporting system.
Arabyat RM; Raisch DW; McKoy JM; Bennett CL
Expert Opin Drug Saf; 2015; 14(11):1653-60. PubMed ID: 26393387
[TBL] [Abstract][Full Text] [Related]
10. Diplopia and fluoroquinolones.
Fraunfelder FW; Fraunfelder FT
Ophthalmology; 2009 Sep; 116(9):1814-7. PubMed ID: 19643481
[TBL] [Abstract][Full Text] [Related]
11. Fluoroquinolone-associated anaphylaxis in spontaneous adverse drug reaction reports in Germany: differences in reporting rates between individual fluoroquinolones and occurrence after first-ever use.
Sachs B; Riegel S; Seebeck J; Beier R; Schichler D; Barger A; Merk HF; Erdmann S
Drug Saf; 2006; 29(11):1087-100. PubMed ID: 17061914
[TBL] [Abstract][Full Text] [Related]
12. Characterization of Immune Checkpoint Inhibitor-Induced Myasthenia Gravis Using the US Food and Drug Administration Adverse Event Reporting System.
Niimura T; Zamami Y; Miyata K; Mikami T; Asada M; Fukushima K; Yoshino M; Mitsuboshi S; Okada N; Hamano H; Sakurada T; Matsuoka-Ando R; Aizawa F; Yagi K; Goda M; Chuma M; Koyama T; Izawa-Ishizawa Y; Yanagawa H; Fujino H; Yamanishi Y; Ishizawa K
J Clin Pharmacol; 2023 Apr; 63(4):473-479. PubMed ID: 36453166
[TBL] [Abstract][Full Text] [Related]
13. Assessing fluoroquinolone-associated aortic aneurysm and dissection: Data mining of the public version of the FDA adverse event reporting system.
Meng L; Huang J; Jia Y; Huang H; Qiu F; Sun S
Int J Clin Pract; 2019 May; 73(5):e13331. PubMed ID: 30809871
[TBL] [Abstract][Full Text] [Related]
14. [Exacerbation of pseudoparalytic myasthenia gravis following azithromycin (Zithromax)].
Cadisch R; Streit E; Hartmann K
Schweiz Med Wochenschr; 1996 Feb; 126(8):308-10. PubMed ID: 8701248
[TBL] [Abstract][Full Text] [Related]
15. Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies.
Gavin JR; Kubin R; Choudhri S; Kubitza D; Himmel H; Gross R; Meyer JM
Drug Saf; 2004; 27(9):671-86. PubMed ID: 15230648
[TBL] [Abstract][Full Text] [Related]
16. Torsades de pointes associated with fluoroquinolones.
Owens RC; Ambrose PG
Pharmacotherapy; 2002 May; 22(5):663-8; discussion 668-72. PubMed ID: 12013370
[TBL] [Abstract][Full Text] [Related]
17. Fluoroquinolone-Associated Tendinopathy: Does Levofloxacin Pose the Greatest Risk?
Bidell MR; Lodise TP
Pharmacotherapy; 2016 Jun; 36(6):679-93. PubMed ID: 27138564
[TBL] [Abstract][Full Text] [Related]
18. Quantitative comparison of the convulsive activity of combinations of twelve fluoroquinolones with five nonsteroidal antiinflammatory agents.
Kim J; Ohtani H; Tsujimoto M; Sawada Y
Drug Metab Pharmacokinet; 2009; 24(2):167-74. PubMed ID: 19430173
[TBL] [Abstract][Full Text] [Related]
19. Adverse drug reactions related to the use of fluoroquinolone antimicrobials: an analysis of spontaneous reports and fluoroquinolone consumption data from three italian regions.
Leone R; Venegoni M; Motola D; Moretti U; Piazzetta V; Cocci A; Resi D; Mozzo F; Velo G; Burzilleri L; Montanaro N; Conforti A
Drug Saf; 2003; 26(2):109-20. PubMed ID: 12534327
[TBL] [Abstract][Full Text] [Related]
20. Safety profile of the fluoroquinolones: analysis of adverse drug reactions in relation to prescription data using four regional pharmacovigilance databases in Italy.
Lapi F; Tuccori M; Motola D; Pugi A; Vietri M; Montanaro N; Vaccheri A; Leoni O; Cocci A; Leone R; Conforti A; Moretti U; Sessa E; Mazzaglia G; Mugelli A; Mazzei T; Vannacci A
Drug Saf; 2010 Sep; 33(9):789-99. PubMed ID: 20701411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
